Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Erectile Dysfunction 2Carcinoma 2Urinary Incontinence 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Head and Neck Neoplasms 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Glutamine 2sagopilone 1nicotinamide-beta-riboside 1allantoicase 1Vitamin D 1Vitamin B 6 1Vitamin B 12 1Taxoids 1Tadalafil 1Sirolimus 1Prednisolone 1Paclitaxel 1Minocycline 1Metformin 1Losartan 1Hydroxychloroquine 1G(M1) Ganglioside 1Fatty Acids, Omega-3 1Exercise 1Everolimus 1Etoricoxib 1Ethosuximide 1Epoetin Alfa 1Dietary Supplements 1Dexamethasone 1Cryotherapy 1Bortezomib 1BID protein, human 1Acupuncture Therapy 1Acetylcysteine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Peripheral Nervous System Diseases × Tadalafil × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡